Drug Safety

, Volume 35, Issue 12, pp 1185–1186 | Cite as

Olanzapine in Schizophrenia and Affective Disorders

  • Juan Undurraga
  • Eduard Vieta
  • Mauricio Tohen
  • Francesc Colom


Schizophrenia Bipolar Disorder Haloperidol Olanzapine Drug Exposure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Supported in part by a Josep Font Research Grant from the Hospital Clínic of Barcelona (to Juan Undurraga); the Instituto de Salud Carlos III through the Centro para la Investigación Biomédica en Red de Salud Mental (CIBERSAM) [to Juan Undurraga, Eduard Vieta and Francesc Colom]; a Miguel Servet postdoctoral contract (CP08/00140) and an FIS (PS09/01044) [Francesc Colom]; and the Generalitat de Catalunya to Bipolar Disorders Group (2009 SGR 1022) [Juan Undurraga, Eduard Vieta and Francesc Colom].

Professor Vieta is a consultant or grant recipient with Almirall, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen-Cilag, Jazz, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Sanofi, Servier, Schering-Plough, Shire, Takeda and United Biosource Corporations. Dr Francesc Colom has served as advisory or speaker for the following companies: Adamed, AstraZeneca, Bristol-Myers, Eli-Lilly, GlaxoSmithKline, Lundbeck, MSD-Merck, Otsuka, Pfizer Inc., Sanofi-Aventis, Shire and Tecnifar. He has received copyright fees from Cambridge University Press, Solal Ed., Ars Médica, Giovani Fioriti Ed., Medipage, La Esfera de Los Libros, Morales i Torres Ed, Panamericana, Mayo Ed. and Columna. Dr Mauricio Tohen was an Eli Lilly employee and has received honoraria from or been a consultant for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, Sepracor, Otsuka, Merck, Sunovion, Forest, Lundbeck and Wyeth. His spouse is a current employee and minor stockholder of Eli Lilly. Dr Juan Undurraga declares no conflicts of interest.


  1. 1.
    Moteshafi H, Zhornitsky S, Brunelle S, et al. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf 2012; 35(10): 819–36PubMedCrossRefGoogle Scholar
  2. 2.
    Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl 2007 Aug; 50: S64–70PubMedCrossRefGoogle Scholar
  3. 3.
    Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006 Jan; 67(1): 107–13PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Juan Undurraga
    • 1
  • Eduard Vieta
    • 1
  • Mauricio Tohen
    • 2
  • Francesc Colom
    • 1
  1. 1.Bipolar Disorders Program, Institute of Neuroscience, Hospital Clínic BarcelonaIDIBAPS, CIBERSAM, University of BarcelonaBarcelonaSpain
  2. 2.Division of Mood and Anxiety DisordersUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations